A cardiovascular specialty hospital in north Texas decreased time to diagnosis for patients with cardiogenic shock by more than half, according to a study published in Critical Care Nurse.
Windtree Therapeutics, Inc. (NasdaqCM: WINT) recently showcased promising data on istaroxime, an investigational treatment ...
Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, today announced that ...
Windtree Therapeutics (WINT) announced that Alexandre Mebazaa, MD, one of the world’s recognized leaders in cardiogenic shock, gave a ...
Hosted on MSN21d
Cardiogenic shock team cuts time to diagnosis by halfMore information: Suzanne Krais et al, Improving Cardiogenic Shock Team Activation Through Nurse Education and Alert Implementation, Critical Care Nurse (2024). DOI: 10.4037/ccn2024259 Provided by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback